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Despite recent discoveries in the genetics of sporadic Alzheimer’s disease, there remains substantial
“hidden heritability.” It is thought that some of this missing heritability may be because of geneegene,
i.e., epistatic, interactions. We examined potential epistasis between 110 candidate polymorphisms in
1757 cases of Alzheimer’s disease and 6294 control subjects of the Epistasis Project, divided between
a discovery and a replication dataset. We found an epistatic interaction, between rs7483 in GSTM3 and
rs1111875 in the HHEX/IDE/KIF11 gene cluster, with a closely similar, significant result in both datasets.
The synergy factor (SF) in the combined dataset was 1.79, 95% confidence interval [CI], 1.35e2.36; p ¼
0.00004. Consistent interaction was also found in 7 out of the 8 additional subsets that we examined post
hoc: i.e., it was shown in both North Europe and North Spain, in both men and women, in both those
with and without the ε4 allele of apolipoprotein E, and in people older than 75 years (SF, 2.27; 95% CI,
1.60e3.20; p < 0.00001), but not in those younger than 75 years (SF, 1.06; 95% CI, 0.59e1.91; p ¼ 0.84).
The association with Alzheimer’s disease was purely epistatic with neither polymorphism showing an
independent effect: odds ratio, 1.0; p  0.7. Indeed, each factor was associated with protection in the
absence of the other factor, but with risk in its presence. In conclusion, this epistatic interaction showed
a high degree of consistency when stratifying by sex, the ε4 allele of apolipoprotein E genotype, and
geographic region.
 2013 Elsevier Inc. All rights reserved.hool of Molecular Medical
gham, Nottingham NG7 2UH,
7.
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The etiology of sporadic, late-onset Alzheimer’s disease (AD) is
muchmore complex than that of the familial, early-onset condition,
J.M. Bullock et al. / Neurobiology of Aging 34 (2013) 1309.e1e1309.e71309.e2which displays dominant Mendelian inheritance. The former
depends on both genetic and environmental factors. Uncovering
those factors is made difficult by the small effect size each exhibits.
For many years, only the ε4 allele of apolipoprotein E (APOEε4)was
known as a susceptibility allele for sporadic AD. Recently, other
reproducible gene candidates, such as PICALM, CLU, CR1, and BIN1
(Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010), have
been identified through genome-wide association studies (GWAS).
However, their small effect sizes (odds ratios 1.5) mean that there
still remainsmuchheritability to uncover (Manolio et al., 2009). This
is believed to be primarily because of the genetically complex and
heterogeneous nature of the disorder, with interactions between
multiple genetic mutations and polymorphisms, as well as between
those and other, nongenetic, factors (Bertram and Tanzi, 2004).
The term, epistasis, was originally coined approximately
100 years ago by William Bateson to represent the masking of one
allelic locus by another (Bateson, 1910). Although it has sometimes
been used in awider sense,weuse the termhere conventionally, i.e.,
when an increased risk is only seen in the presence of 2 genetic
factors and not seen when they act apart. Such interactions may be
one cause of the hidden heritabilitymentioned above. In such cases,
studies that examine single loci individually, such as GWAS, will fail
to detect an effect. Examples of epistasis in genetic studies on Alz-
heimer’s disease have been reviewed by Combarros et al. (2009a).
Though GWAS have proven effective in detecting single-locus
effects, such an unbiased approach might not be appropriate for
the studyof epistasis. A typical GWASmayexamineperhaps 500,000
loci but the number of potential 2-way interactions between those
500,000 loci is more than 100 billion (1011). In order therefore to
reduce the number of potential interactions to a manageable figure,
a hypothesis-driven approach might be required.
The approach we adopted is shown in Fig. 1 (Study design). We
first carried out a systematic review of claims of epistasis in
sporadic AD (Combarros et al., 2009a). From that investigation, we
selected 31 genes, involved in 32 interactions, with biological
plausibility and previous evidence of association with AD. We have
previously replicated several of those interactions (Combarros et al.,
2009b, 2010; Heun et al, 2012; Kölsch et al., 2012; Lehmann et al.,
2012). In this study, we looked instead for potential binary inter-
actions not previously examined. To do that, we used a discoveryFig. 1. Study design. Experimental design for selecting genes and single-ndataset of 1366 AD cases and 1184 controls and a replication set of
391 AD cases and 5111 controls, both drawn from the Epistasis
Project (Fig. 1).
We discovered and replicated an interaction between two single
nucleotide polymorphisms (SNPs), rs7483 and rs1111875. Rs7483 is
in the GSTM3 gene, encoding glutathione S-transferase m3, involved
in the detoxification of products of oxidative stress in the brain
(Mannervik and Danielson, 1988). Rs1111875 is in the gene cluster
of the hematopoietically expressed homeobox (HHEX), the insulin-
degrading enzyme (IDE), and the kinesin family member 11 (KIF11).
Associations with AD have previously been reported in this region
(Carrasquillo et al., 2010).
2. Methods
2.1. Subjects
The Epistasis Project aims to study interactions between genetic
loci that affect the risk of AD. It is a collaboration of 7 AD research
groups: Bonn, Bristol, Nottingham, Oviedo, Oxford (OPTIMA), Rot-
terdam, and Santander. Sample characteristics by geographic region
are given in Supplementary Table 1. All AD cases were diagnosed
“definite” or “probable” by Consortium to Establish A Registry for
Alzheimer’s Disease (CERAD) (Mirra et al.,1993) orNational Institute
of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann et al., 1984) criteria. AD cases were sporadic,
i.e., possible autosomal dominant cases were excluded, based on
family history. The median ages (interquartile ranges) of cases were
79.0 (73.0e85.2) and of controls were 76.9 (71.3e83.0). Full details
of our sample sets and genotyping methods are given elsewhere
(Combarros et al., 2009b). Rs7483 and rs1111875 were directly
genotyped, not imputed. Research ethics approval was obtained by
each of the participating groups (Supplementary Table 2). All
participants of the study gave informed written consent.
2.2. Selection and screening of candidate interactions
Fig. 1 describes our study design in detail. Major features
included: a systematic literature review of epistasis in sporadic ADucleotide polymorhphisms (SNPs) for study in the Epistasis Project.
Table 1
Interaction in AD risk between rs7483 AAþAG versus GG and rs1111875 GG versus
GAþAA in the hypothesis-generating and replication datasets
Dataset Numbers Powera Adjustedb SF 95% CI p value
Control AD
Discovery 982 1102 93% 1.88 1.27e2.79 0.0016
Replication 4939 375 81% 1.91 1.25e2.93 0.003
Combined 5921 1477 99% 1.79 1.35e2.36 0.00004
Key: AD, Alzheimer’s disease; APOEε4, the ε4 allele of apolipoprotein E; CI, confi-
dence interval; SF, synergy factor.
a Power to detect a synergy factor of 1.8 at p < 0.05.
b Controlling for age, study center, sex, and APOEε4 genotype.
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genes with previous evidence of interactions; the screening of
potential interactions in a discovery dataset, followed by the
replication of the highlighted interaction in a separate set, and
further subset analysis to confirm the interaction (Fig. 1).
2.3. Statistical analysis
For screening the –epistasis module in the PLINK (version 1.07)
whole-genome analysis toolkit was used, with the recommended
filtering threshold of p < 104 (Purcell et al., 2007). For all further
analyses (Fig.1),weused logistic regressionmodels inRVersion2.12.1
(R Development Core Team, 2008), controlling for age, study center,
sex, and APOEε4 genotype in all analyses. The best fitting model was
selected using Akaike’s Information Criterion. Analyses were carried
out first in the 6-center discovery set (Fig. 1), then in the Rotterdam
replication set.Weanalyzedeachcenter independently, aswell as the
2 geographical regions of North Europe (Bonn, Bristol, Nottingham,
Oxford, and Rotterdam) and North Spain (Oviedo and Santander). In
addition we also examined the interaction (identified in our screen,
see section 3.1.) when stratified by age, sex, or APOEε4 genotype, and
the 3-way interactions of these 2 SNPs with age, sex, and APOEε4.
Heterogeneity among centers and overdispersionwas controlled
for as described elsewhere (Combarros et al., 2010). Epistasis was
established using synergy factor (SF) analysis; this approach
measures the size and significance of an interaction (Cortina-Borja
et al., 2009). It is calculated as the ratio of the observed odds ratio
for both factors combined to the predicted odds ratio assuming
independent effects of each factor. A brief explanation of SF analysis
is given in Box 1 of Combarros et al. (2009a); a full explanation is
given in Cortina-Borja et al. (2009). Power calculations were based
on the observed SF values, using the method described previously
(Cortina-Borja et al., 2009). Allelic frequencies between North Spain
and North Europe were compared using Fisher’s exact test. All tests
of significance and power calculations were 2-sided.
2.4. Exploring functional mutations
Inanattempt tounderstand the functionalbasis of the interaction,
we established the linkage disequilibrium block in which the SNPs
were operating using SNAP Proxy (Johnson et al., 2008). SNPnexus
andF-SNPwereused toprioritize functional proxieswithin these loci
(Chelala et al., 2009; Lee and Shatkay, 2008).We also used publically
available expression data for quantitative trait loci to identify poly-
morphisms regulating the expression of interacting genes and Fun-
Coup to explore any evidence of biological interaction (Alexeyenko
and Sonnhammer, 2009; Dixon et al., 2007; Myers et al., 2007).
3. Results
3.1. Screening for interactions
A single 2-way interaction, between rs7483 in GSTM3 and
rs1111875 in the HHEX/IDE/KIF11 gene cluster, was highlighted by
the –epistasis module in PLINK among the 110 candidate poly-
morphisms in the 6-center discovery cohort as being below the
filtering threshold, i.e., 1  104; odds ratio, 0.67; p ¼ 3.16  105.
This threshold was used to identify potential interactions that
possibly merit further study. The minor allele frequency of rs7483
(A allele) was 29% in North Europe and 26.5% in North Spain, while
that of rs1111875 (A allele) was 41% in North Europe and 37% in
North Spain (Supplementary Table 3). Genotype distributions in all
7 centers are given in Supplementary Table 4.
Analysis with R allowed for the specification of the interaction
model used in the logistic regression calculations, as well as forcontrolling for covariates. Of the 4 combinations of minor or major
allele-dominant pairings for the 2 SNPs, the best fit by Akaike’s
Information Criterion and the greatest significance was observed
with a minor allele-dominant model for both SNPs (SF, 1.88; 95%
confidence interval [CI], 1.27e2.79, p ¼ 0.0016) in the discovery set
(Table 1).
Calculating the interaction in the Rotterdam replication set
produced consistent results, with the samemodel showing the best
fit. This was further reinforced when all 7 centers were combined
(Table 1). Examining the odds ratio of each factor separately
showed that neither SNP was independently associated with AD,
i.e., all odds ratios were very close to 1.0 (Table 2).
The 3-way interaction of the 2 SNPs with age as a continuous
variable was significant (p ¼ 0.002), as was that with age75 years
(p ¼ 0.02), but not that with age 80 years (p ¼ 0.06) (the median
ages of cases and controls were 79.0 and 76.9 years, respectively).
There were no 3-way interactions with sex or APOEε4 (p ¼ 0.38 and
0.86, respectively).
3.2. Post hoc stratification
Because the 2-way interaction between rs7483 in GSTM3 and
rs1111875 in the HHEX/IDE/KIF11 gene cluster (Table 1) would not
survive strict Bonferroni correction for all potential binary inter-
actions (n ¼ 5995), we conducted subset analysis to confirm the
generality of the result. In the combined dataset (Table 3), signifi-
cant results were found in men and women, and also in those with
at least 1 copy of APOEε4 (APOEε4þ) and those without (APOEε4).
In contrast, stratification by age produced a clear difference: highly
significant results were seen in people older than the age of
75 years (p < 0.00001), but not in those younger than 75 (p ¼ 0.84)
(Table 3). Further analysis was therefore restricted to people older
than 75 years (Tables 4e6).
3.3. Consistent effects between regions and centers
The results from the 2 geographic regions, North Europe and
North Spain, were consistent (Table 4), as were those of the 7
centers (Table 5). All 7 SFs pointed in the same direction (SF >1)
including the 4 sets with low power (13%e24%) to replicate the
interaction (Table 5). Additionally, the 2 sets with >50% power to
detect the interaction reached significance (Rotterdam: SF, 2.03;
95% CI, 1.26e3.26; p ¼ 0.0036; and Santander: SF, 3.58; 95% CI,
1.39e9.22; p ¼ 0.009). There was heterogeneity in the SF values
between centers which is unsurprising, given the low power (<25%,
Table 5) inmore than half of the centers. However, we controlled for
this heterogeneity in all combined analyses.
3.4. The epistatic effect
The 2 interacting risk factors were the GSTM3 rs7483 A allele and
the HHEX/IDE/KIF11 rs1111875 GG genotype. As a further test for
Table 4
The interaction between rs7483 AAþAG vs GG and rs1111875 GG vs GAþAA in people
75 years of age
Dataset Adjusteda SF 95% CI p-value
Discovery 2.96 1.72e5.08 0.00009
Replication 2.03 1.26e3.26 0.0036
North Europe 2.19 1.48e3.26 0.0001
North Spain 2.80 1.22e6.41 0.015
Combined 2.27 1.60e3.20 <0.00001
‘North Europe’ comprises Bonn, Bristol, Nottingham, Oxford, and Rotterdam; ‘North
Spain’ comprises Oviedo and Santander. See Supplementary Table 3 for the numbers
from North Europe and North Spain.
Key: APOEε4, the ε4 allele of apolipoprotein E; CI, confidence interval; SF, synergy
factor.
a Controlling for age, study center, sex, and APOEε4 genotype.
Table 5
The interaction between rs7483 AAþAG versus GG and rs1111875 GG versus GAþAA
in people 75 years of age and older, by center
Table 2
Odds ratios of AD for rs7483 AAþAG versus GG and rs1111875 GG versus GAþAA
SNP Dataset Adjusteda odds ratio 95% CI p-value
rs7483 Discovery 0.96 0.80e1.16 0.68
Replication 0.97 0.80e1.19 0.80
Combined 0.98 0.86e1.12 0.81
rs1111875 Discovery 1.01 0.83e1.23 0.92
Replication 1.02 0.83e1.26 0.85
Combined 1.00 0.87e1.14 0.97
Key: AD, Alzheimer’s disease; APOEε4, the ε4 allele of apolipoprotein E; CI, confi-
dence interval; SNP, single nucleotide polymorphism.
a Controlling for age, study center, sex, and APOEε4 genotype.
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versus the absence of the interacting factor. Each factor was asso-
ciated with an increased risk in the presence of the other factor and
was protective in its absence (Table 6). Results obtained in the
discovery and replication sets (data not shown) were consistent
with those in the combined dataset (Table 6).
4. Discussion
4.1. Interpretation of results
We have identified an interaction associated with AD risk,
between rs7483 in GSTM3 and rs1111875 in the HHEX/IDE/KIF11
gene cluster, in our discovery and replication datasets (Table 1). Not
only have we shown the interaction in our total dataset (1757 AD,
6292 controls), but to demonstrate the generality and robustness of
the interaction, we also found it in post hoc analyses of an addi-
tional 7 out of 8 subsets. It was shown throughout the European
populations we used, both in North Europe and in North Spain
(Tables 4 and 5). It was seen in both men and women, and both in
those with and without the APOEε4 allele (Table 3). It appeared,
however, to be limited to people older than the age of 75 (Tables 3
and 4), consistent with the significant 3-way interaction between
the 2 SNPs and age (section 3.4.). This older subset had slightly
greater power to detect the interaction (with an SF of 2.3): 99.8%
power compared with 89% power in those younger than 75 years.
Nevertheless, the marked contrast in results in those older than
75 years (SF, 2.27; 95% CI, 1.60e2.20; p < 0.00001), compared with
those in individuals younger than 75 years (SF, 1.06; 0.59e1.91; p ¼
0.84) (Table 3), suggests that our findings might indeed be limited
to older people. The effect was purely epistatic: neither SNP showed
any main effect overall (Table 2); this result would not therefore
have been detected by any GWAS reported to date. In epistasis, the
effect of each genetic risk factor should be significantly different in
the presence versus the absence of the interacting factor, as was the
case here (Table 6).
Hong et al. (2009) had found an association with AD of GSTM3
SNPs, particularly rs1799735, possibly interacting with APOEe4.Table 3
The interaction between rs7483 AAþAG versus GG and rs1111875 GG versus GAþAA
in various subsets
Subseta Adjustedb SF 95% CI p-value
Men 1.64 1.01e2.68 0.046
Women 1.95 1.38e2.76 0.00016
APOEε4þ 1.63 1.01e2.64 0.046
APOEε4 1.79 1.27e2.51 0.0009
75 y 2.27 1.60e3.20 <0.00001
<75 y 1.06 0.59e1.91 0.84
Key: APOEε4, the ε4 allele of apolipoprotein E; CI, confidence interval; SF, synergy
factor.
a See Supplementary Table 5 for the numbers in each subset.
b Controlling for age, study center, sex, and APOEε4 genotype.Rs1799735 is inweak linkage disequilibrium (LD) with rs7483 (D’¼
1.00; r2 ¼ 0.07). In preliminary analyses in a subset of our data, our
results were consistent with those of Hong et al. Thus, that asso-
ciation merits further study.
4.2. HHEX/IDE/KIF11 rs1111875
Rs1111875 is located on chromosome 10 in a 58 kb block of tight
LD (r2 > 0.6; chr10 coordinates 94,414,402e94,472,056) encom-
passing HHEX. Rs1111875 falls 7.5 kb downstream of HHEX in
a conserved domain. A GWAS signal for type 2 diabetes has been
tracked to 2 linked SNPs in this region (rs1111875 and rs5015480,
r2 ¼ 0.97), although the functional mutation is yet to be described
(Sladek et al., 2007; Zeggini et al., 2007). Of the 9 SNPs in high LD
with rs1111875 (r2 > 0.8), none fall within a gene or a predicted
functional region.
Upstream of rs1111875, there is an extended LD block of 299 kb
(r2 > 0.5; chr10 coordinates 94,192,885e94,491,751) which
contains 2 additional genes (IDE and KIF11) which might hold
functional variants (Fig. 2). However, our attempts to prioritize
candidate SNPs using functional prediction (F-SNP and SNPnexus)
have offered little insight. Interestingly, rs1111875 is in modest LD
(r2 ¼ 0.47) with the intronic IDE SNP, rs6583817, which has shown
association with AD, increased IDE mRNA levels in AD cerebellum
and reduced levels of serum b-amyloid 40. Luciferase reporter
assays suggested the minor allele increases IDE expression in
a neuroblastoma cell line (Carrasquillo et al., 2010).
In a further attempt to establish which gene within this locus
tracks with rs1111875, we have also used expression data for
quantitative trait loci from two previous studies. Unfortunately, one
study did not measure the expression of IDE, HHEX, or KIF11 (Myers
et al., 2007). Although the data of the other study, Dixon et al.,Centre Numbers (75 y) Adjusteda synergy factor
(95% CI, p)
Powerb
Control AD
Bonn 55 84 1.92 (0.29e12.6, 0.50) 24%
Bristol 36 129 5.51 (0.82e36.8, 0.08) 15%
Nottingham 41 44 2.49 (0.27e23.1, 0.43) 13%
OPTIMA 140 148 2.81 (0.91e8.61, 0.07) 45%
Oviedo 27 142 1.05 (0.13e8.14, 0.96) 15%
Rotterdam 2917 351 2.03 (1.26e3.26, 0.004) 95%
Santander 262 166 3.58 (1.39e9.22, 0.009) 58%
Combined 3478 1064 2.27 (1.60e3.20, <0.00001) 99.8%
Key: AD, Alzheimer’s disease; APOEε4, the ε4 allele of apolipoprotein E; CI, confi-
dence interval; OPTIMA, Oxford Project To Investigate Memory and Ageing.
a Controlling for age, sex, APOEε4 genotype and, in the combined analysis, study
center.
b Power to detect a synergy factor of 2.27 at p < 0.05.
Table 6
Odds ratios of AD for rs7483 AAþAG versus GG and rs1111875 GG versus GAþAA in the presence or absence of each other, in people 75 years of age and older
Odds ratio of AD for: In the subset: Numbers Adjusteda odds ratio of AD (95% CI, p)
Controls AD
rs7483 AGþAA versus GG rs1111875 GG AGþAA: 584 AGþAA: 222 1.70 (1.28e2.27, 0.0003)
GG: 705 GG: 175
rs1111875 AGþAA AGþAA:1164 AGþAA: 315 0.74 (0.61e0.91, 0.004)
GG: 1180 GG: 429
rs1111875 GG versus AGþAA rs7483 AGþAA GG: 584 GG: 222 1.49 (1.17e1.90, 0.001)
AGþAA:1164 AGþAA: 315
rs7483 GG GG: 705 GG: 175 0.66 (0.51e0.84, 0.001)
AGþAA:1180 AGþAA: 429
Key: AD, Alzheimer’s disease; APOEε4, the ε4 allele of apolipoprotein E; CI, confidence interval.
a Controlling for age, study center, sex, and APOEε4 genotype.
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significantly associated with SNPs in this locus (Dixon et al., 2007).
Attempts to look at functional interaction between IDE/HHEX/KIF11
and known AD candidate genes (using FunCoup; Alexeyenko and
Sonnhammer, 2009) also failed to elevate the candidacy of any 1
gene.
Though IDE might seem to be the obvious candidate because of
its established role in the degradation of b-amyloid, the other 2
genes merit some attention. HHEX has been associated with poor
forebrain neurodevelopment in HHEX (/) mutants (Martinez
Barbera et al., 2000). A recent meta-analysis implicated rs1111875,
which is 30 of the HHEX gene, in the risk of type 2 diabetes, although
the function of this SNP is yet to be assessed (Wang et al., 2011).
Type 2 diabetes is itself a risk factor for AD. Members of the kinesin
family (KIF) have been implicated in microtubule axonal transport
of amyloid precursor protein (APP) from the latter’s synthesis sites
in the neuronal cell body to the terminus. This activity is afforded by
APP binding to the light chain of the KIF protein. Mutant KIF
proteins have been studied in mice and a reduced capacity for APP
microtubule binding, and thus for transport, was identified (Feuk
et al., 2005; Kamal et al., 2000).
Consequently, at present it is not possible to select any particular
gene within this extended LD block as the definitive candidate,Fig. 2. Linkage disequilibrium (LD) architecture of the locus containing HHEX/KIF11/IDE. Rs
polymorhphisms (SNPs) surrounding HHEX. Upstream of rs1111875 is a large block of mod
high recombination (dashed vertical lines). Image generated with SNAP proxy server (Maesdespite using a number of bioinformatic approaches; at the
moment the evidence supports any or all of these genes being
implicated when rs1111875 is used as a tag.4.3. GSTM3 rs7483
Rs7483 is located in the GSTM3 gene and affects transcription of
that gene (Maes et al., 2010). The GSTM3 protein has long been
shown to be related to detoxification of the effects of oxidative
stress (Mannervik and Danielson, 1988), particularly in the brain
(Aksenov, 2001). Detoxification of a variety of carcinogens takes
place in the cytosol of cells via the activity of glutathione S-trans-
ferase (GST) enzymes. Polymorphisms in the genes for these
enzymes have been linked to certain carcinomas in a variety of
populations (Yengi et al., 1996). One report has identified the
presence of GSTM1 on the inner membrane of mitochondria in
humans (Gallagher et al., 2006). Based on this study, it has been
suggested that GST enzymes might play a role in the detoxification
of carcinogens and reactive oxygen species (ROS) in the cytosol and
the mitochondria. Consequently, risk alleles at GST loci may also
demonstrate altered function and therefore increase the risk of
damage from ROS (Datta et al., 2007).1111875, located downstream of HHEX, is in high LD (r2 > 0.8) with single-nucleotide
est linkage (r2 > 0.5) encompassing KIF11 and IDE, after which LD is broken down by
et al., 2010).
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with the aging process, and to be particularly prominent in the
proteins of AD patient brain tissues (Aksenov, 2001). This is
consistent with our finding being limited to people older than the
age of 75. The oxidative stress hypothesis for AD affords that axonal
transport of mitochondria is functionally impaired, resulting in the
production of ROS (Pappolla et al., 1992). Finally, it has been
observed that GSTM3 is also expressed in distinct patterns in the
brain tissue of AD patients, which is particularly noticeable in the
plaques and tangles that are diagnostic of AD and in the activated
microglia surrounding those plaques (Tchaikovskaya et al., 2005).
This last observation suggests that inflammation might also be
involved in this interaction.
5. Conclusions
We have confirmed an interaction between the HHEX/IDE/KIF11
locus (rs1111875) and GSTM3 (rs7483) that is associated with AD
risk through replication in 2 cohorts and through post hoc stratifi-
cation by sex, APOEε4, and geographic region. Post hoc analyses also
suggested that the effect was mainly or solely in people older than
75 years. Although we were unable to pinpoint 1 gene in particular
from the HHEX/IDE/KIF11 locus as being tagged by rs1111875, it has
been shown that IDE is inactivated when subjected to chemically
induced oxidative stress (Shinall et al., 2005). Given the importance
of GST enzymes in the prevention of oxidative stress in the brain,
this suggests a potential functional interaction. However, we cannot
rule out other possible mechanisms, e.g., inflammation.
Attempts at further replication of these results in European or
other ethnic groups should be limited to large datasets, i.e., with at
least 1000 cases and 1000 controls. Such datasets would have at
least 91% power to replicate the above interaction, assuming similar
allelic frequencies as in this study, and a synergy factor of 1.8,
whereas datasets with only 200 cases and 200 controls, for
instance, would have only 38% power.
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